BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Le P, Rothberg MB. Determining the Optimal Vaccination Schedule for Herpes Zoster: a Cost-Effectiveness Analysis. J Gen Intern Med 2017;32:159-67. [PMID: 27743284 DOI: 10.1007/s11606-016-3844-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
Number Citing Articles
1 Le P, Rothberg MB. Cost-effectiveness of the Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults. JAMA Intern Med 2018;178:248-58. [PMID: 29297049 DOI: 10.1001/jamainternmed.2017.7431] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 17.5] [Reference Citation Analysis]
2 Leidner AJ, Murthy N, Chesson HW, Biggerstaff M, Stoecker C, Harris AM, Acosta A, Dooling K, Bridges CB. Cost-effectiveness of adult vaccinations: A systematic review. Vaccine 2019;37:226-34. [PMID: 30527660 DOI: 10.1016/j.vaccine.2018.11.056] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 12.0] [Reference Citation Analysis]
3 Reddy KP. Herpes Zoster Vaccine: Time for a Boost? J Gen Intern Med 2017;32:145-7. [PMID: 27730484 DOI: 10.1007/s11606-016-3885-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
4 Hurley LP, Allison MA, Dooling KL, O'Leary ST, Crane LA, Brtnikova M, Beaty BL, Allen JA, Guo A, Lindley MC, Kempe A. Primary care physicians' experience with zoster vaccine live (ZVL) and awareness and attitudes regarding the new recombinant zoster vaccine (RZV). Vaccine 2018;36:7408-14. [PMID: 30420121 DOI: 10.1016/j.vaccine.2018.09.018] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
5 Warren-Gash C, Forbes H, Breuer J. Varicella and herpes zoster vaccine development: lessons learned. Expert Rev Vaccines 2017;16:1191-201. [PMID: 29047317 DOI: 10.1080/14760584.2017.1394843] [Cited by in Crossref: 24] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
6 Chiyaka ET, Nghiem VT, Zhang L, Deshpande A, Mullen PD, Le P. Cost-Effectiveness of Herpes Zoster Vaccination: A Systematic Review. PharmacoEconomics 2019;37:169-200. [DOI: 10.1007/s40273-018-0735-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
7 Gabutti G, Bolognesi N, Sandri F, Florescu C, Stefanati A. Varicella zoster virus vaccines: an update. Immunotargets Ther 2019;8:15-28. [PMID: 31497569 DOI: 10.2147/ITT.S176383] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
8 Le P, Rothberg MB. Cost Effectiveness of a Shingles Vaccine Booster for Currently Vaccinated Adults in the U.S. American Journal of Preventive Medicine 2017;53:829-36. [DOI: 10.1016/j.amepre.2017.08.029] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
9 Curran D, Patterson B, Varghese L, Van Oorschot D, Buck P, Carrico J, Hicks K, Lee B, Yawn B. Cost-effectiveness of an Adjuvanted Recombinant Zoster Vaccine in older adults in the United States. Vaccine 2018;36:5037-45. [DOI: 10.1016/j.vaccine.2018.07.005] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 8.0] [Reference Citation Analysis]
10 Hoshi S, Kondo M, Okubo I. Cost-effectiveness of varicella vaccine against herpes zoster and post-herpetic neuralgia for elderly in Japan. Vaccine 2017;35:3264-71. [DOI: 10.1016/j.vaccine.2017.04.046] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]